Tvardi Therapeutics Inc. (TVRD)
NASDAQ: TVRD
· Real-Time Price · USD
29.39
-3.49 (-10.61%)
At close: May 23, 2025, 3:59 PM
29.50
0.37%
After-hours: May 23, 2025, 07:24 PM EDT
Company Description
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Tvardi Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 16, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Imran Alibhai Ph.D. |
Contact Details
Address: 2450 Holcombe Blvd, Suite X Sugar Land, Texas United States | |
| Website | https://tvarditherapeutics.com BioSpace +4 |
Stock Details
| Ticker Symbol | TVRD |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001742947 |
| CUSIP Number | 140755307 |
| ISIN Number | US1407553072 |
| Employer ID | 82-3784554 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Dr. Imran Alibhai Ph.D. | Chief Executive Officer & Director |
| Dan Conn J.D., M.B.A. | Chief Financial Officer |
| David J. Tweardy M.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of R&D |
| Dr. John Kauh M.D. | Chief Medical Officer |
| Dr. Michael T. Lewis Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
| Stephen O'Brien CPA | Vice President of Finance & Corporate Controller |
| Wallace Hall Jr. | Founder, President & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2021 | D | Filing |
| Jul 30, 2018 | D/A | [Amend] Filing |
| Jun 08, 2018 | D | Filing |